Muscular effects of statins in the elderly female: A review

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 47-59

  Bhardwaj, Shilpa ^a   Selvarajah, Shalini ^b   Schneider, Eric B ^c  

^a Griffin Hospital   (United States)

^b YALE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Elderly; Epidemiology; Females; Older adults; Statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTIN; CYCLOSPORIN; DILTIAZEM; FARNESYL DIPHOSPHATE; GEMFIBROZIL; GERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NEFAZODONE; ORGANIC ANION TRANSPORTER 2; PHENYTOIN; PLACEBO; PYROPHOSPHORIC ACID DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; UNCLASSIFIED DRUG;

AGED; APOPTOSIS; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; COMORBIDITY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEG CRAMP; LOW DRUG DOSE; MONOTHERAPY; MUSCLE CELL; MYALGIA; MYOPATHY; MYOSITIS; PHARMACOGENETICS; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; SEX DIFFERENCE; SIDE EFFECT; SLCO1B1 GENE; STATIN INDUCED MYOPATHY; SUSTAINED RELEASE FORMULATION;

ELDERLY; EPIDEMIOLOGY; FEMALES; OLDER ADULTS; STATINS;

AGED; AGING; CELL DEATH; COMORBIDITY; DRUG INTERACTIONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MUSCULAR DISEASES; MYOSITIS; POLYISOPRENYL PHOSPHATES; QUALITY OF LIFE; RHABDOMYOLYSIS; SESQUITERPENES; SEX FACTORS; UBIQUINONE;

EID: 84872981869     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. National Center for Health Statistics. Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville (MD): National Center for Health Statistics; 2011.
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366: 1267-1278.
3. Walsh JME, Pignone M. Drug treatment for hyperlipidemia in women. JAMA. 2004;291:2243-2252.
4. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360: 7-22.
5. Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in the use of cholesterol-lowering agents in older adults: the cardiovascular health study. Arch Intern Med. 1998;158:1761-1768.
6. Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol. 2012;159: 169-176.
7. Bays H. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol. 2006;97:6C-26C.
8. IMS Institute for Health Informatics. The Use of Medicines in the United States: Review of 2011. Parsippany, NJ: IMS Institute for Health Informatics; 2012. Available from: http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf. Accessed October 15, 2012.
9. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106:1024-1028.
10. McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol. 2006;97:89C-94C.
11. Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23: 317-324.
12. Alexander KP, Blazing MA, Rosenson RS, et al. Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther. 2009;14: 49-58.
13. Gaist D, Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12:565-569.
14. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858-868.
15. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;7(352):1425-1435.
16. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690.
17. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29:1761-1770.
18. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005;19: 403-414.
19. Newman CB, Szarek M, Colhoun HM, et al. The safety and tolerability of atorvastatin 10 mg in the collaborative atorvastatin diabetes study (CARDS). Diab Vasc Dis Res. 2008;5:177-183.
20. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163: 553-564.
21. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same? Drug Saf. 2002;25:649-663.
22. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104:109-124.
23. Insull W Jr, Isaacsohn J, Kwiterovich P, et al. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. J Int Med Res. 2008;28:47-68.
24. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006;97:44C-51C.
25. Center for Drug Evaluation and Research. Baycol medical review. 1999. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-740S008_Baycol_medr.pdf. Accessed October 10, 2012.
26. Boetje M, Bunout D, Barrera G, de la Maza MP, Leiva L, Hirsch S. Effects of statin use on functional capacity and muscle mass in elderly women. Ageing Res. 2011;2:35-39.
27. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59:572-582.
28. Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol. 2009;22:506-515.
29. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis. 2009; 202:18-28.
30. Nishimoto T, Tozawa R, Amano Y, Wada T, Imura Y, Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol. 2003;66:2133-2139.
31. Matzno S, Yamauchi T, Gohda M, et al. Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. J Lipid Res. 1997;38:1639-1648.
32. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49: 2231-2237.
33. Bełtowski J, Wójcicka G, Jamroz-Wiśniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf. 2009;4: 209-228.
34. Chatzizisis YS, Vaklavas C, Giannoglou GD. Coenzyme Q10 depletion: Etiopathogenic or predisposing factor in statin associated myopathy? Am J Cardiol. 2008;101:1071.
35. Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve. 2005;31:572-580.
36. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 1998;83:490-500.
37. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210:337-343.
38. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6-14.
39. ElDesoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther.2007;14:488-498.
40. Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40: 188-194.
41. Szadkowska I, Stanczyk A, Aronow WS, et al. Statin therapy in the elderly: a review. Arch Gerontol Geriatr. 2010;50:114-118.
42. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83:1-10.
43. Hofer-Dueckelmann C, Prinz E, Beindl W, et al. Adverse drug reactions (ADRs) associated with hospital admissions - elderly female patients are at highest risk. Int J Clin Pharmacol Ther. 2011;49:577-586.
44. Fattinger K, Roos M, Vergères P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol. 2000;49:158-167.
45. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998;38:1003-1009.
46. Ciccone GK, Holdcroft A. Drugs and sex differences: a review of drugs relating to anaesthesia. Br J Anaesth. 1999;82:255-265.
47. Sica DA, Gehr TWB. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol. 2002;11:48-55.
48. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003;38:978-988.
49. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol.1999;84:811-815.
50. Yoshida M, Matsumoto T, Suzuki T, Kitamura S, Mayama T. Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker. Pharmacoepidemiol Drug Saf. 2008;17:70-75.
51. Kaikkonen J, Nyyssönen K, Tuomainen TP, Ristonmaa U, Salonen JT. Determinants of plasma coenzyme Q10 in humans. FEBS Lett. 1999; 443:163-166.
52. Racine M, Tousignant-Laflamme Y, Kloda LA, Dion D, Dupuis G, Choinière M. A systematic literature review of 10 years of research on sex/gender and pain perception - part 2: do biopsychosocial factors alter pain sensitivity differently in women and men? Pain. 2012;153:619-635.
53. Goffaux P, Michaud K, Gaudreau J, Chalaye P, Rainville P, Marchand S. Sex differences in perceived pain are affected by an anxious brain. Pain. 2011;152:2065-2073.
54. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34:153-162.
55. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy - a genome-wide study. N Engl J Med. 2008;359: 789-799.
56. Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012;92:112-117.
57. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82:726-733.
58. Brunham LR, Lansberg PJ, Zhang L, et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012;12:233-237.
59. Santos PC, Soares RA, Nascimento RM, et al. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet. 2011;12: 136.
60. Ruaño G, Windemuth A, Wu AH, et al. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis. 2011;218:451-456.
61. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics. 2005;15:415-421.
62. Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97:69C-76C.
63. Blom DJ. Statin therapy for the octogenarian? J Endocrinol Metab Diabetes South Afr. 2012;17:37-42.
64. Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc. 2003;78:1564-1577.
65. Arora R, Liebo M, Maldonado F. Statin-induced myopathy: the two faces of Janus. J Cardiovasc Pharmacol Ther. 2006;11:105-112.
66. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmakonietics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455-463.
67. Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles heel? Curr Med Res Opin. 2011;27: 1551-1562.
68. Jones P, Davidson M. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2006;95:120-122.
69. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-581.
70. Parker BA, Augeri AL, Capizzi JA, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109: 282-287.
71. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165:2671-2676.
72. Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther. 2003;17:459-465.
73. Mascitelli L, Pezzetta F. Does statin therapy interfere with the ability of claudicant patients to exercise? Vasc Endovascular Surg. 2007;41: 473.
74. Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol. 2008;17:92-100.
75. Kulik A, Ruel M. Statins and coronary artery bypass graft surgery: preoperative and postoperatice efficacy and safety. Expert Opin Drug Saf. 2009;8:559-571.
76. Desai H, Aronow WS, Ahn C, et al. Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins. Arch Gerontol Geriatr. 2010;51:149-151.
77. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
78. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
79. Spósito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999;83:1497-1499.
80. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170: 1524-1530.
81. Lemoine S, Allouche S, Coulbault L, et al. Mechanisms involved in cardioprotective effects of pravastatin administered during reoxygenation in human myocardium in vitro. Anesthesiology. 2012;116:824-833.
82. Osmak M. Statins and cancer: current and future prospects. Cancer Lett. 2012;324:1-12.
83. Lutski M, Shalev V, Porath A, Chodick G. Continuation with statin therapy and the risk of primary cancer: a population-based study. Prev Chronic Dis. 2012;9:E137.
84. Schneider EB, Efron DT, MacKenzie EJ, Rivara FP, Nathens AB, Jurkovich GJ. Premorbid statin use is associated with improved survival and functional outcomes in older head-injured individuals. J Trauma. 2011;71:815-819.
85. Maroo BP, Lavie CJ, Milani RV. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike? Drugs Aging. 2008;25: 649-664.
86. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864-1870.
87. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008;8: 333-338.